Cannabidiol (CBD) rich products are successfully used in some countries for treating symptoms associated with autism spectrum disorder (ASD). Yet, CBD provides insufficient intervention in some individuals, or for some characterizing symptoms of ASD, raising the need for improved compositions. The current study presents a case wherein pure CBD was sufficient for treating ASD during childhood and early adolescence. However, it became insufficient during puberty accompanied by increased hyperactivity, agitation, and frequent severe aggressive behavior. Increasing the CBD dose did not result in significant improvement. Enriching the pure CBD with a carefully selected blend of anxiolytic and calming terpenes, resulted in gradual elimination of those aggressive events. Importantly, this was achieved with a significantly reduced CBD dose, being less than one-half the amount used when treating with pure CBD.
Differences between therapeutic effects of medical cannabis inflorescences and those of their extracts are generally attributed to the differences in administration form and in the resultant pharmacokinetics. We hypothesized that difference may further extend to the composition of the actually consumed drug. Cannabinoid and terpene contents were compared between commercial cannabis inflorescences (n = 19) and decarboxylated extracts (n = 12), and between inflorescences and decarboxylated extracts produced from them (n = 10). While cannabinoid content was preserved in the extracts, a significant loss of terpenes was evident, mainly in the more volatile monoterpenes
Medical cannabis products contain dozens of active pharmaceutical ingredients (APIs) derived from the cannabis plant. However, their actual compositions and relative doses significantly change according to the production methods. Product compositions are strongly dependent on processing step conditions and on components’ evaporation during those steps. Review of the documentation presented to caregivers and to patients show erroneous data or misinterpretation of data related to the evaporation, for example, cannabinoids’ boiling points, as well as confusions between terms, such as boiling, vaporization, and evaporation. Clarifying these aspects is
essential for caregivers, for researchers, and for developers of manufacturing processes. Original and literature data were analyzed, comparing composition changes during various processing steps and correlating
Bazelet has invented a unique way of formulating of medical cannabis oils. Bazelet, doesn’t depend on developing new strains in order to form a large variety of better-performing new oils. Instead, Bazelet’s TOP technology generates improved new oils by blending extracts and by controlling their terpene content, particularly by enriching with scientific-based terpenes selection.
Cannabis inflorescence contains 10-20 different terpenes, varying in amount and proportion and determining the characteristic aroma of the various strains. Processing modifies the terpenes content and, most importantly the terpene profile. Terpenes content of oils is, in many cases, less than one half that of inflorescence and the proportion of low-boiling point terpenes in oil is much smaller than that in the inflorescence.
But this is not mainly about aroma. Terpenes play an important medical role, individually (as in aromatherapy) and, more importantly, in modulating the activity of the cannabinoids in the cannabis oil. Generating oils of exactly selected terpenes composition is easy and is achieved by simple industrial processes. Undesired terpenes are removed by evaporation, while desired terpenes are added, typically ones sourced from plants other than cannabis, e.g. lavender and citrus. The terpene content of Bazelet oils is 50-100% greater than those of common cannabis oils and are therefore referred to as terpenes-enriched.
While manufacturing many formulations of exact composition is straightforward, the main challenge is to discover the preferred composition for each indication or symptom. Some players in the cannabis industry try to collect as much of the terpenes lost during processing and add them back to the oil in order to regenerate the terpene profile of the inflorescence. This approach is questionable, keeping in mind the obvious – the terpene profile of each strain is selected by nature to serve the needs of the plant, e.g. protection from plant diseases, rather than to serve human needs.
Bazelet launches its Bcann Oil brand, which is first-of-the kind, proprietary, terpene-enriched medical cannabis oils specially designed for medical needs such as women health, pain treatment, improved sleep and special needs of the elderly population
Bazelet, the largest medical company in Israel, has made a breakthrough in medical cannabis products, in launching multiple lines of terpene-enriched cannabis oils, each one of which being specifically designed for one of various indications, symptoms and personal needs. Bazelet terpene-enriched products are optimized for woman health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic), and for improved night sleep etc.
Bazelet’s scientific paper dealing with medical cannabis treatment in various neurological conditions was published in the Neurology journal, the official journal of the Israel Neurological association.
Cannabis products and industrial methods for production thereof. A homogeneous composition comprising cannabinoid-containing comminuted cannabis plant material, where at least 70% weight of the comminuted cannabis plant material is of a size greater than 0.3 millimeter and less than 4.2 millimeters; the composition comprises at least 1% by weight moisture and less than 20% by weight moisture; and the cannabinoid concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the cannabinoid concentration in a separate 1 gram fraction of said 10 gram sample
A cannabis-enriched enzymatically treated therapeutic composition. A therapeutic composition is described including water, glucose, glucose reaction product other than sucrose and fructose; a selected amount of a cannabinoid, a cannabinoid reaction product; optionally a terpene and optionally a terpene reaction product. Methods of making and using the compositions are also described.